This hottest twist within the Lykos Therapeutics saga threatens a major overhaul of the corporate’s approach and path, with Musk ally and billionaire investor Antonio Gracias showing up to choose to acquire the corporate again toward its nonprofit drug growth roots and a far more Doblinite philosophy.Disclaimer: copyright Highlight and its mother